Evidence map›Paper›PMID 41889788›Full record

ArticlePalliative care and social practice2026

Temporal trends and predictors of inpatient palliative care in metastatic upper urinary tract carcinoma: An observational study.

Carolin Siech, Lukas Scheipner, Andrea Baudo, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Fred Saad, Shahrokh F Shariat, Nicola Longo, Luca Carmignani and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Palliative care and social practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Carolin SiechCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.ORCID https://orcid.org/0000-0002-5460-4171
Lukas ScheipnerCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Andrea BaudoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Mario de AngelisCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Letizia Maria Ippolita JannelloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Francesco Di BelloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Italy.
Luca CarmignaniDepartment of Urology, IRCCS Policlinico San Donato, Milan, Italy.
Ottavio de CobelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Sascha AhyaiDepartment of Urology, Medical University of Graz, Austria.
Alberto BrigantiDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Cristina Cano GarciaGoethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.
Luis A KluthGoethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.
Felix K H ChunGoethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rates and patterns of inpatient palliative care (IPC) use in metastatic upper urinary tract carcinoma (mUTC) are largely unknown. Objectives: To assess temporal trends and predictors of IPC in patients with mUTC. Design: Relying on the National Inpatient Sample (2008-2019), we identified 3563 mUTC United States inpatients. Methods: Estimated annual percentage changes (EAPC) analyses as well as logistic regression models addressing IPC use were fitted. Subgroup analyses addressed IPC use according to the number and location of metastatic sites. Results: Of 3563 mUTC inpatients, 540 (15%) received IPC. Overall, the rate of IPC increased from 2 to 22% between 2008 and 2019 (EAPC +10%). In subgroup analyses, the highest increase in IPC use was observed in patients with liver metastases (from 3 to 33%; EAPC + 11%), in patients with bone metastases (from 3 to 29%; EAPC: +10%), and in patients with three or more metastatic sites (from 0.5 to 31%; EAPC: 10%; all Conclusion: The IPC rate in mUTC was very low (15%). However, this rate increased to approximately 22% in 2019. The highest IPC rates were recorded in contemporary liver (33%), bone (29%), and three or more metastatic sites (31%) United States inpatients. Therefore, clinicians should be sensitized to early IPC use in mUTC patients in general as well as in other metastatic distribution patterns.

Indexed as

in-hospital mortalitymetastatic stageNISpalliative careUTUC

Identifiers

PMID41889788
PMCPMC13013996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.